What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 1).

December 8, 2025BloodOpen Access

All 19 subjects with transfusion-dependent β-thalassemia achieved transfusion independence after treatment with RM-001 (autologous HBG1/2 promoter-modified CD34+ hematopoietic stem and progenitor cells)

View Full Paper

Ask AI

Bookmark

Authors

Phase 1 trial shows RM-001 improves fetal hemoglobin levels in transfusion-dependent β-thalassemia, suggesting potential for cure.

All 19 subjects achieved transfusion independence and maintained stable hemoglobin levels after RM-001 treatment.
Mean total hemoglobin levels increased to 12.0 g/dL by month 18, indicating success in treatment.
The Phase 1 trial focused on evaluating RM-001's safety and efficacy through CRISPR-Cas9 gene editing.
No serious adverse events were reported, highlighting the excellent safety profile of RM-001.

Liu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase 1 trial shows RM-001 improves fetal hemoglobin levels in transfusion-dependent β-thalassemia, suggesting potential for cure.

All 19 subjects achieved transfusion independence and maintained stable hemoglobin levels after RM-001 treatment.
Mean total hemoglobin levels increased to 12.0 g/dL by month 18, indicating success in treatment.
The Phase 1 trial focused on evaluating RM-001's safety and efficacy through CRISPR-Cas9 gene editing.
No serious adverse events were reported, highlighting the excellent safety profile of RM-001.

Liu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark